Adenoid cystic carcinoma

Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting

Retrieved on: 
화요일, 3월 5, 2024
SAN, IRF4, Senior, KRON, Research, Research and development, Adenoid cystic carcinoma, AACR, Molecular biology, Gene expression, Abstract, Multiple myeloma, CDK9, KAT, Development, Cancer, Pharmaceutical industry

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that three abstracts have been selected for presentation at the American Association for Cancer Research (AACR) annual meeting, being held from April 5-10, 2024 in San Diego, California.

Key Points: 
  • SAN MATEO, Calif. and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that three abstracts have been selected for presentation at the American Association for Cancer Research (AACR) annual meeting, being held from April 5-10, 2024 in San Diego, California.
  • “We are excited to present our data at AACR showing that targeting p300’s enzymatic KAT domain can selectively downregulate IRF4, a long sought after transcription factor dependency in multiple myeloma.
  • Although p300 is an essential gene, our data show that through its relationship as a critical IRF4 cofactor, we can achieve selective antiproliferative effects against myeloma cells,” said Charles Lin, Ph.D., Senior Vice President, Research and Development of Kronos Bio.
  • Details for the AACR 2024 abstracts are as follows:
    Title: A dose escalation and cohort expansion study of the CDK9 inhibitor KB-0742 in relapsed, refractory and transcriptionally addicted solid tumors
    Title: KB-0742, an oral highly selective CDK9 inhibitor, demonstrates preclinical activity in transcription factor fusion driven adenoid cystic carcinoma patient-derived models
    Poster Session: Molecular Biology in Clinical Oncology: Characterizing and Modulating Epigenetics and Gene Expression

Vietnam Veteran marks holidays and birthdays at Cleveland Fisher House

Retrieved on: 
화요일, 11월 28, 2023
Fisher House, Mask, Walking, Meal, Family, Cleveland Clinic, New Year's Day, Friends, Adenoid cystic carcinoma, Microwave, Cancer, Hatboro, Pennsylvania, Food, Fisher House (Hatboro, Pennsylvania), THANK, Radiation

David is a veteran who was diagnosed with cancer that necessitated almost two months of treatment in Cleveland.

Key Points: 
  • David is a veteran who was diagnosed with cancer that necessitated almost two months of treatment in Cleveland.
  • The couple spent the entirety of the 2020-2021 holiday season at the Cleveland Fisher House.
  • After meeting with a social worker, she suggested the Fisher House would be the best place for us to spend our 54 days in Cleveland.
  • It is very hard to express in words what the Fisher House has done for my husband and myself.

Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies in Patients with Solid Tumors and AML/HR-MDS, and Presents the Updated Development Plan for RVU120

Retrieved on: 
월요일, 10월 23, 2023
Medulloblastoma, Bone marrow, Plasma, AUC, Acute myeloid leukemia, Cmax, ESMO, Erythropoiesis, Principal investigator, Aes, PD, Congress, MD, Adenoid cystic carcinoma, CEST, Ruxolitinib, Cell, Data, Syndrome, All-comers track meet, Phase, SD, Risk, Webcast, Pancreatic cancer, Venetoclax, NPM1, WSE, ADCC, Safety, European Society for Medical Oncology, Patient, AML, Sarcoma, Pharmaceutical industry, Medical imaging, Dietary supplement

The total budget for the Phase II clinical development of RVU120 aligns with the estimates initially announced in the Ryvu Development Plans for 2022-2024.

Key Points: 
  • The total budget for the Phase II clinical development of RVU120 aligns with the estimates initially announced in the Ryvu Development Plans for 2022-2024.
  • The presented RVU120 development plan aligns with the budget outlined in Ryvu Development Plans for 2022-2024 and targets multi-billion-dollar market potential.
  • At the ESMO Congress 2023, Ryvu announced updated clinical Phase I data from Phase I/II study of RVU120 in relapsed/refractory metastatic advanced solid tumors.
  • Ryvu will host a webinar today (Monday, October 23) at 9:00 am CEST to discuss further RVU120 development plans.

Research Conducted by Florida Cancer Specialists & Research Institute Featured at European Society of Medical Oncology 2023 Congress

Retrieved on: 
금요일, 10월 20, 2023
Research, Annals of Oncology, ESMO, SERD, Physician, MAPK, Congress, European Society for Medical Oncology, Estate (law), Drug development, B7-H4, Adenoid cystic carcinoma, FIH, Abstract, Oncology, Safety, Cancer, FCS, ATR, Patient, Diagnosis, Conjugation, Pharmaceutical industry, MD

FORT MYERS, Fla., Oct. 20, 2023 /PRNewswire/ -- Research conducted by Florida Cancer Specialists & Research Institute, LLC (FCS) is featured this week among the latest advancements and findings in cancer care at the European Society of Medical Oncology (ESMO) Congress in Madrid, Spain. Five FCS physicians are the first authors and/or co-authors of 12 cancer research studies that will be shared at the global gathering of oncologists, researchers, patient advocates, pharmaceutical representatives and journalists. With more than 30,000 members from 168 countries worldwide, ESMO is the leading professional organization for medical oncology.

Key Points: 
  • FORT MYERS, Fla., Oct. 20, 2023 /PRNewswire/ -- Research conducted by Florida Cancer Specialists & Research Institute, LLC (FCS) is featured this week among the latest advancements and findings in cancer care at the European Society of Medical Oncology (ESMO) Congress in Madrid, Spain.
  • With more than 30,000 members from 168 countries worldwide, ESMO is the leading professional organization for medical oncology.
  • The ESMO Congress 2023 is a global stage for the exchange of potentially practice-changing data and multidisciplinary conversations that will spur transformative therapies against cancer.
  • All of the study abstracts will be published online in the ESMO Congress 2023 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology.

Elevar Therapeutics Names Dr. Chris Galloway Vice President of Clinical Development

Retrieved on: 
화요일, 8월 15, 2023
University, Moses Austin, Hepatocellular carcinoma, Diffusion Pharmaceuticals, Adenoid cystic carcinoma, DaVita Inc., Liver cancer, MD, Patient, Biology, Merck, PD-1, Hypoxia, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, UTHealth School of Dentistry, Food, Pharmaceutical industry

FORT LEE, N.J., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced the hiring of Dr. Chris Galloway as vice president of clinical development.

Key Points: 
  • FORT LEE, N.J., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced the hiring of Dr. Chris Galloway as vice president of clinical development.
  • At Elevar, he’ll lead a talented team of medical professionals developing the company’s current portfolio and play a key strategic role in identifying and driving new assets and indications.
  • “Elevar Therapeutics is currently active in all stages of clinical development and Dr. Chris Galloway’s breadth of experience makes him a perfect addition to our talented team,” said Elevar Chief Executive Officer Saeho Chong.
  • Galloway holds an MD from the University of Texas Medical Branch at Galveston and bachelor’s degree in biology from the University of Texas at Austin.

Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
목요일, 8월 10, 2023
Columbia University, ACC, Plantar fibromatosis, Financial result, ESMO, Survival, Adenoid cystic carcinoma, ASCO, Congress, American Society of Clinical Oncology, Patient, OTCQX, Ayala, Security (finance), European Society for Medical Oncology, Research, FDA, Berlin, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PSA, Society, Food, Prostate cancer, Pharmaceutical industry, Rare-earth element, Clothing

REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced second-quarter 2023 financial results and provided a corporate update.

Key Points: 
  • Definitive merger agreement with Biosight, expected to close near end of Q3 2023
    REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced second-quarter 2023 financial results and provided a corporate update.
  • Gain clarity on path for future development plan for AL101 in recurrent/metastatic adenoid cystic carcinoma (R/M ACC), expected in 2023.
  • Consolidated Financial Results for the Second Quarter Ended June 30, 2023
    Cash position On June 30, 2023, the Company’s consolidated cash and cash equivalents position was $7.1 million.
  • For further details on the Company’s financial results, including results for the six-month period ended June 30, 2023, refer to our quarterly report on Form 10-Q for the quarter ended June 30,2023, filed with the Securities and Exchange Commission.

Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

Retrieved on: 
수요일, 8월 9, 2023
CDK, Clinical trial, Adenoid cystic carcinoma, Research, PLK1, Endometrial cancer, Patient, Cyclacel, Webcast, R, Ovarian cancer, CYCC, Research and development, Fine chemical, Pharmaceutical industry, Cryptocurrency, Broadcasting

BERKELEY HEIGHTS, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical leader in cell cycle checkpoint control developing innovative medicines based on cancer cell biology, announced today second quarter financial results and provided a business update.

Key Points: 
  • BERKELEY HEIGHTS, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical leader in cell cycle checkpoint control developing innovative medicines based on cancer cell biology, announced today second quarter financial results and provided a business update.
  • The operating plan includes discretionary expenditures, which if not incurred could extend liquidity requirements into the second quarter of 2024.
  • General and administrative expenses for the three months ended June 30, 2023 and 2022, remained relatively flat at $1.6 million.
  • Webcast link
    For the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel website at www.cyclacel.com .

Elevar Therapeutics Announces Publication of Phase 3 CARES 310 Study Results in The Lancet

Retrieved on: 
화요일, 7월 25, 2023
Camrelizumab, ACC, Hepatocellular carcinoma, Progression-free survival, Food, TKI, Adenoid cystic carcinoma, Prescription Drug User Fee Act, Patient, Sorafenib, PDUFA, PD-1, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HCC, Pharmaceutical industry, Lancet

FORT LEE, N.J., July 24, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced the publication of its Phase 3 CARES 310 study results in The Lancet.

Key Points: 
  • FORT LEE, N.J., July 24, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced the publication of its Phase 3 CARES 310 study results in The Lancet.
  • The study assessed the combination of Elevar’s drug candidate rivoceranib, an oral TKI, in combination with camrelizumab, a PD-1 inhibitor, as a first-line therapy for unresectable hepatocellular carcinoma (uHCC).
  • “As evidenced in the CARES 310 study, camrelizumab plus rivoceranib demonstrate significant promise as a potentially improved therapy for advanced hepatocellular carcinoma,” said Saeho Chong, Elevar chief executive officer.
  • With efficacy results generally consistent across all subgroups, the CARES 310 data suggested the combination confers a benefit in a global uHCC population.

Elevar Therapeutics to Participate in ASCO 2023 and BIO 2023; New Jersey-based Company Secures State License as It Builds Toward Commercialization

Retrieved on: 
목요일, 6월 1, 2023
ACC, BIO, Partnership, Hepatocellular carcinoma, McCormick Place, Biotechnology, NDA, Licensure, TKI, Adenoid cystic carcinoma, Research, ASCO, Organization, American Society of Clinical Oncology, Patient, Annual general meeting, Convention center, Boston Convention and Exhibition Center, PD-1, FDA, Therapy, Regulation of tobacco by the U.S. Food and Drug Administration, Society, HCC, Food, New Drug Application, Pharmaceutical industry

Presentation details are as follows:

Key Points: 
  • Presentation details are as follows:
    Elevar also will attend BIO 2023, to be held June 5-8 at the Boston Convention & Exhibition Center in Boston, as it seeks partnership for global commercialization of rivoceranib.
  • In March, Elevar announced its move to a new corporate headquarters in Fort Lee, New Jersey.
  • It has now obtained its New Jersey Resident State Facility Inspection Report and is a licensed pharmaceutical wholesaler in the state, part of its strategic nationwide state licensing process.
  • We look forward to gaining licensure in every U.S. state as we prepare for commercialization of rivoceranib.”

Oxford BioTherapeutics announces Phase 1b trial in collaboration with GORTEC to investigate OBT076 in Adenoid Cystic Carcinoma (ACC) of the head and neck

Retrieved on: 
수요일, 4월 19, 2023
Learning, ACC, Partnership, CPI, Neoplasm, OBT, Head, Lausanne University Hospital, NSCLC, Radiation therapy, Doctor of Philosophy, Neck, Radiation, MD, Patient, Risk, CD205, ADC, PD-1, Recurrence, Adenoid cystic carcinoma, Metastasis, Disease, Pharmaceutical industry

ACC is a rare, aggressive type of cancer which represents 2% of head and neck cancers and about 20% of salivary gland malignancies.

Key Points: 
  • ACC is a rare, aggressive type of cancer which represents 2% of head and neck cancers and about 20% of salivary gland malignancies.
  • OBT has observed the drug receptor CD205, a unique characteristic for this disease, in at least 80% of ACC patients.
  • CD205 is the target for OBT’s innovative ADC, OBT076, suggesting that OBT076 may have high therapeutic potential in this type of cancer.
  • It will investigate OBT076 both as a monotherapy and in combination with Agenus Inc. proprietary checkpoint inhibitor (CPI), balstilimab.